Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04812626 |
| Other study ID # |
BPK |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
January 28, 2021 |
| Est. completion date |
September 14, 2021 |
Study information
| Verified date |
March 2021 |
| Source |
B.P. Koirala Institute of Health Sciences |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Summary: Keloids and hypertrophic scars are benign fibrous growth, differing mainly by
overgrowth beyond the initial defect in keloid whereas hypertrophic scar is confined to
initial lesion and tends to regress over the years. Keloids and hypertrophic scars mainly
lead to cosmetic disfigurement and functional deformity depending on site of involvement, in
addition to symptoms like pain and pruritus, encountered occasionally. These sometimes might
lead to psychological impact too. Different treatment options for keloids and hypertrophic
scar are silicone gel/ sheets, corticosteroids, cryotherapy, lasers, antineoplastic agents
(5-FU, mitomycin-C), surgical excision and immunomodulators (imiquimod) used either as
monotherapy or combination therapy. Different studies involving combination of TAC and 5-FU
have been done so far which shows better treatment outcome in terms of efficacy and safety.
In a recent meta-analysis published in 2017 concluded that combination therapy of 5-FU + TAC
offers better outcome than TAC alone, however recommended additional randomized, controlled,
large-sample, high quality trial are needed for a more objective analysis of the treatment
efficacy and to assess the adverse reaction associated. We are conducting this study the
objective to compare the efficacy and safety profile of intralesional triamcinolone acetonide
alone and its combination with 5-FU of the treatment of keloids and hypertrophic scars. This
study may help in finding out the optimum treatment option in keloid and hypertrophic scar
with minimal side effects in our clinical practice.
Description:
HYPOTHESIS Null hypothesis: There is no difference in the efficacy of intralesional
triamcinolone acetonide alone and its combination with 5-flurouracil in the treatment of
keloids and hypertrophic scars Alternate hypothesis: Combination of intralesional
triamcinolone and 5- fluorouracil is more efficacious than intralesional triamcinolone alone
in treatment of keloids and hypertrophic scars
METHODS
Sample size: Sample size:
This study considers a 95% confidence interval, 80% power to estimate sample size. According
to the article published in the Clinical and experimental dermatology by Darougegh A et al in
2009 comparing the efficacy of Intralesional Triamcinolone alone versus combined with 5 FU in
treatment of keloids, it was found that the patient reported good to excellent (> 50%) 30 | P
a g e improvement in TAC alone group was 20% whereas that of the combination of TAC and 5-FU
was 55% (22). Now using the sample size estimation formula for 2 proportions based on above
study, n = {2p(1-p) (Zβ + Zα/2)2}/ (p1-p2)2 Where n= sample size for each group; p1 = 0.55;
p2 = 0.2; p= (p1 +p2)/2; Zα/2=1.96 at 95% CI; Zβ = 0.842 at 80% power; using above formula,
n= 30. Adding 10% in calculated value to consider the drop out, the minimum sample size in
each group will be 30+3=33; Thus, a total sample size will be 66 The study is double blinded
,both participants and investigator( treatment provider/assessor) are blinded. Total of 66
patients are enrolled into the study , 33 in each groups allocated by block randomization
through computer generated block randomization list. Patients with a clinical diagnosis of
keloids or hypertrophic scars attending the outpatient department of dermatology at BPKIHS
will be enrolled in the study. Written and understood informed consent will be taken prior to
the enrollment and treatment. Detailed information of all the patients satisfying inclusion
criteria will be recorded in preset pro forma. This will include personal data, past history,
medical history, drug history, clinical data like site, size, number, distribution of
lesions, complaints related to scar like pain, pruritus, erythema, scar score and cutaneous
examination. Patients will be excluded according to the exclusion criteria. Photographs of
the lesions will be taken before the first treatment session, in every treatment session and
at the completion of treatment at 12th week. Only one lesion (preferably on the trunk or
proximal extremity) will be treated per patient.
Study Treatments:
Each patient will be assigned a patient identity number and will be allocated to receive
either triamcinolone acetonide alone (1ml of 40mg/ml triamcinolone acetonide will be mixed
with 1ml of normal saline) or triamcinolone acetonide and 5-FU combination (1ml of 40 mg/ml
triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU) depending upon the treatment
specified in the sealed opaque envelope.
Treatment will be provided as follows:
Group A: Intralesional Triamcinolone only One ml of 40mg/ml triamcinolone acetonide will be
mixed with 1ml of normal saline to make a 20mg/ml concentration.
Group B Intralesional Triamcinolone + 5 fluorouracil One ml of 40 mg/ml triamcinolone
acetonide will be mixed with 1ml of 50 mg/ml FU with resulting mixture TAC/5-FU concentration
being 20mg/25mg per ml .
Treatment duration: 10 weeks (drug given at 0,2, 4, 6,8,10 weeks)
Post treatment follow up: at 12 weeks.
Assessment:
During treatment and during follow-ups, the scar will be assessed for the following:
1. Length, width and height of the scar: using Vernier calipers and digital photography
2. POSAS scoring:
3. Vancouver Scar Scale (VSS)
4. Subjective improvement: Overall improvement as graded by patient and observer separately
on a 5 point scale and percentage in improvement is assessed in each follow up visit
(no/poor: up to 25% , fair: 26-50%, good: 51-75%, excellent : 76-100% improvement) and
efficacy is determined by good to excellent improvement( improvement >50%) in patient
and observer reported separately
Efficacy evaluation:
The primary efficacy endpoints will be calculated on the basis of the percent reduction from
baseline to week 12 in the subjective improvement, lesion size and scar scores and taking
single lesion as the reference lesion in a patient (in case of multiple number of lesions
under treatment in a single patient). The response rates (percentage of patients achieving
50% reduction in size of scar, percentage of patient achieving good to excellent subjective
improvement) will also be compared at 12 weeks in each treatment group.
Safety evaluation: Safety of treatment is assessed through evaluation of local adverse
effects like erythema, pain, atrophy, ulceration, telangiectasia, pigmentation and systemic
effects if any like Cushing's syndrome in each follow up visit week 2, 4, 6, 8, 10 and 12.
Statistical analysis Data will be entered in Microsoft Excel 2016 (Microsoft Corporation,
Redmond, Washington, USA) and statistical analysis will be done using Statistical Package for
the Social Sciences 11.5 version (Chicago, Inc). Statistical analysis will be conducted both
per-protocol and intention-to treat population (defined as all enrolled patients to whom
study drug will be given; with the last observation carried forward) basis using two sided
tests.
For descriptive statistics, percentage, mean, Standard Deviation, median, interquartile range
and minimum, maximum will be calculated along with graphical and tabular presentation. For
inferential statistics, statistical methods proposed are as follow Chi square test , Paired t
test ,Independent 't' test ,Wilcoxon signed rank test , Mann- Whitney U test , Kaplan-Meier
curves The test of significance will be considered when the value of p< 0.05
